Your session is about to expire
← Back to Search
AB-101 + Immunotherapy for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer treatment made of "natural killer" cells, which are part of the immune system. The treatment will be given to patients with relapsed or refractory Non-Hodgkin lymphoma of B-cell origin, in order to determine if it is effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My brain lymphoma is in remission for at least 3 months.My lung function is not normal.I have had a stem cell transplant from a donor.My heart's pumping ability is below 45%.I have tried at least two treatments for my condition, including one with anti-CD20 therapy.Your disease can be evaluated using the Lugano classification criteria.I have been diagnosed with a type of non-Hodgkin lymphoma that comes from B-cells.I do not have any ongoing, uncontrolled infections.I have a serious heart condition.I have a history of organ transplant or diseases worsened by IL-2.I agree to use birth control during and up to 6 months after the trial.
- Group 1: Phase 1: Dose confirmation of AB-101 as mono, ritux combo (including DLBCL specific) & BR combo
- Group 2: Phase 2: AB-101 given with rituximab or with BR to patients with B-cell NHL at the R2PD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical facilities are conducting this research project?
"The primary locations for this research are University of California, Irvine; Oregon Health Sciences Center; and University of Iowa Hospitals and Clinics. There are also 10 other sites across the country where this study is taking place."
Is this research project still recruiting participants?
"The clinicaltrials.gov website indicates that this study is still recruiting patients. The initial posting was on 29 March 2021, with the most recent update taking place 31 May 2022."
What are the most common indications for AB-101?
"AB-101 has been traditionally used to ameliorate symptoms for patients with lung cancer, however it can also be given as a treatment for b-cell lymphomas, multiple sclerosis and polyangium."
Are there other similar experiments underway that include AB-101?
"There are 1215 ongoing studies and 227 in Phase 3 that are researching AB-101. Some of the trials for AB-101 are based out of Philadelphia, but there are a total of 36963 clinical trial locations for AB-101."
Share this study with friends
Copy Link
Messenger